Stockreport

Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF to Rezurock (belumosudil) for treating chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and above weighing at least 40 kg. This conditi [Read more]